Evercore ISI Removes Krystal Biotech (KRYS) From Tactical Outperform List
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 26, 2024 8:00 AM ESTÂ Net product revenue of $42.1M in 4Q and $50.7M for the year
  New England Journal of Medicine publication of the use of B-VEC eyedrop formulation
  Reached alignment with FDA to enable approval of B-VEC eyedrop formulation for the treatment of lesions in the eye of DEB patients
  First patient dosed in Phase 1 KB408 trial for the treatment of AATD; five active clinical trials in 2024
  Strong balance sheet, closing the year with $594.1M in cash and investments
